JPMorgan cuts Xylem to underweight, lowers target to $90
JPMorgan cut its rating on Xylem from neutral to underweight and lowered its price target from $118 to $90.
JPMorgan cut its rating on Xylem from neutral to underweight and lowered its price target from $118 to $90.